Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1996 April; 73(8): 966–971.
PMCID: PMC2075811

Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine.


Human diploid fibroblasts growth normally in medium containing physiological concentrations of the naturally occurring dipeptide carnosine (beta-alanyl-L-histidine). These concentrations are cytotoxic to transformed and neoplastic cells lines in modified Eagle medium (MEM), whereas these cells grow vigorously in Dulbecco's modified Eagle medium (DMEM) containing carnosine. This difference is due to the presence of 1 mM sodium pyruvate in DMEM. Seven human cell lines and two rodent cell lines were tested and all are strongly inhibited by carnosine in the absence of pyruvate. Experiments with HeLa cells show that anserine is similar to carnosine, but D-carnosine and homocarnosine are without effect. Also, the non-essential amino acids alanine and glutamic acid contribute to the effect of pyruvate in preventing carnosine toxicity, and oxaloacetate and alpha-ketoglutarate can substitute for pyruvate. We have used mixtures of normal MRC-5 fibroblasts and HeLa cells to demonstrate that 20 mM carnosine can selectively eliminate the tumour cells. This has obvious implications which might be exploited in in vivo and in vitro studies. Carnosine is known to react strongly with aldehyde and keto groups of sugars by Amadori reaction, and we propose that it depletes certain glycolysis intermediates. It is well known that tumour cells are more dependent on glycolysis than normal cells. A reduction of glycolysis intermediates by carnosine may deplete their energy supply, but this effect is totally reversed by pyruvate.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973 Nov;51(5):1417–1423. [PubMed]
  • Hipkiss AR, Michaelis J, Syrris P, Kumar S, Lam Y. Carnosine protects proteins against in vitro glycation and cross-linking. Biochem Soc Trans. 1994 Nov;22(4):399S–399S. [PubMed]
  • Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett. 1995 Aug 28;371(1):81–85. [PubMed]
  • Huschtscha LI, Holliday R. Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts. J Cell Sci. 1983 Sep;63:77–99. [PubMed]
  • Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979 Jul;17(1):16–23. [PubMed]
  • McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res. 1994 Jun;212(2):167–175. [PubMed]
  • Mannion AF, Jakeman PM, Dunnett M, Harris RC, Willan PL. Carnosine and anserine concentrations in the quadriceps femoris muscle of healthy humans. Eur J Appl Physiol Occup Physiol. 1992;64(1):47–50. [PubMed]
  • Martinez AO, Norwood TH, Prothero JW, Martin GM. Evidence for clonal attenuation of growth potential in HeLa cells. In Vitro. 1978 Dec;14(12):996–1002. [PubMed]
  • Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm Park Dis Dement Sect. 1994;8(3):193–208. [PubMed]
  • Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med. 1992;13(5):379–444. [PubMed]
  • Rhim JS, Cho HY, Huebner RJ. Non-producer human cells induced by murine sarcoma virus. Int J Cancer. 1975 Jan 15;15(1):23–29. [PubMed]
  • Röllinghoff M, Warner NL. Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells. Proc Soc Exp Biol Med. 1973 Dec;144(3):813–818. [PubMed]
  • Russell PJ, Wotherspoon J, Jelbart M, Philips J, Raghavan D. Stability of lectin binding properties expressed by human bladder carcinoma cell lines passaged in vitro or in nude mice. Urol Res. 1988;16(6):407–414. [PubMed]
  • Shapot VS. Some biochemical aspects of the relationship between the tumor and the host. Adv Cancer Res. 1972;15:253–286. [PubMed]
  • WARBURG O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309–314. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK